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ABSTRACT
Nicotinamide phosphoribosyltransferase (NAMPT) is a crucial enzyme in the 
biosynthesis of intracellular NAD+. NAMPT inhibitors have potent anticancer activity 
in several preclinical models by depleting NAD+ and ATP levels. Recently, we 
demonstrated that CD73 enables the utilization of extracellular NAD+/nicotinamide 
mononucleotide (NMN) by converting them to Nicotinamide riboside (NR), which can 
cross the plasmamembrane and fuel intracellular NAD+ biosynthesis in human cells. 
These processes are herein confirmed to also occur in a human ovarian carcinoma cell 
line (OVCAR-3), by means of CD73 or NRK1 specific silencing. Next, we investigated 
the anti-tumor activity of the simultaneous inhibition of NAMPT (with FK866) and CD73 
(with α, β-methylene adenosine 5′-diphosphate, APCP), in an in vivo human ovarian 
carcinoma model. Interestingly, the combined therapy was found to significantly 
decrease intratumor NAD+, NMN and ATP levels, compared with single treatments. 
In addition, the concentration of these nucleotides in ascitic exudates was more 
remarkably reduced in animals treated with both FK866 and APCP compared with 
single treatments. Importantly, tumors treated with FK866 in combination with APCP 
contained a statistically significant lower proportion of Ki67 positive proliferating cells 
and a higher percentage of necrotic area. Finally, a slight but significant increase in 
animal survival in response to the combined therapy, compared to the single agents, 
could be demonstrated. Our results indicate that the pharmacological inhibition of 
CD73 enzymatic activity could be considered as a means to potentiate the anti-cancer 
effects of NAMPT inhibitors.
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INTRODUCTION
Cells utilize nicotinamide adenine dinucleotide 
(NAD+) either as a coenzyme in redox reactions or 
as a substrate for NAD+-degrading enzymes, such as 
poly(ADP-ribose) polymerases (PARPs), ectocellular 
NAD+ases, including CD38 and sirtuins (SIRT1–7) [1]. 
Previously, our group reported that CD73, mostly known 
as the ectoenzyme dephosphorylating extracellular AMP to 
adenosine, is in fact also capable of degrading both NAD+ 
and NMN: specifically, CD73 degrades NAD+ to NMN 
and AMP, which are subsequently dephosphorylated by 
the same enzyme to NR and adenosine, respectively [2]. 
NAD+ metabolism plays a crucial role in the fate of 
tumor cells and cellular NAD+ levels are the result of a fine 
balance between opposite processes of NAD+ synthesis 
and degradation.
In mammalian cells, NAD+ is mainly 
synthesized from nicotinamide (NAM) through a 
salvage pathway sequentially involving the enzymes 
NAM phosphoribosyltransferase (NAMPT), which 
produces NMN, and NMN adenylyltransferase, which 
synthesizes NAD+ from NMN and ATP [3–5]. NAMPT 
is overexpressed in different types of cancer, including 
prostate, gastric, breast and ovarian cancer, gliomas, 
leukemia, lymphoma and myeloma [6, 7]. The mechanism 
by which NAMPT is fundamental in tumor progression 
certainly relies on the fact that NAD+ is required for the 
activity of NAD+-metabolizing enzymes, such as PARP1, 
SIRT1, SIRT6 and CD38, all having different cancer-
promoting abilities, such as genomic stability, secretion 
of pro-inflammatory cytokines, angiogenesis, motility and 
invasion [8–11]. 
NAMPT inhibitors, including FK866 and CHS828, 
have potent anticancer activity in several preclinical 
models of solid and hematologic cancers [6] by depleting 
NAD+ and ATP levels and thereby leading to tumor growth 
inhibition [6–8, 12–15]. 
Despite their promise in preclinical models, in 
phase I/II clinical studies, FK866 and CHS828 essentially 
failed to show signs of a meaningful anticancer activity in 
patients with solid tumors [16]. Regarding safety of these 
compounds, the main forms of reported toxicity were 
thrombocytopenia, various gastrointestinal symptoms and 
lymphopenia [6]. Also based on these results, currently, 
there is a general agreement on the fact that NAMPT 
inhibitors should be administered in combination with 
other treatments, to increase their efficacy [6, 8]. One 
suggested possibility is the combination of NAMPT 
inhibitors with PARP-activating chemotherapeutics, 
which should further enhance the decrease in intracellular 
NAD+ content [17, 18]. Based on an opposite rationale, 
NAMPT inhibition has also been proposed to synergize 
with PARP inhibitors in triple-negative breast cancer [19]. 
NAMPT inhibition was also found to increase the efficacy 
of Tumor Necrosis Factor-Related Apoptosis Inducing 
Ligand (TRAIL), HDAC inhibitors, P-glycoprotein-1 
(Pgp) inhibitors and of Rituximab, an anti-CD20 antibody, 
in leukemia cells [20–23]. Finally, NAMPT inhibition 
enhanced the effect of radiation in an in vivo prostate 
cancer model [24].
A plausible explanation for the limited activity of 
single-agent NAMPT inhibitors as cancer therapeutics 
in clinical trials could be the presence in human body 
fluids of NAD+ or NAD+ precursors, including nicotinic 
acid (NA), NMN and NR, which could well substitute 
for the inhibited NAD+ biosynthesis from NAM [25]. 
Indeed, NAD+ and NMN have been detected in mammal 
plasma and fluids [26, 27]. NAD+ efflux from cells can 
occur through a non-specific cell death, or through Cx43 
hemichannels, with a regulated mechanism [28, 29].
Recently, we demonstrated that endogenous CD73 
enables the utilization of extracellular NAD+/NMN as a 
precursor for intracellular NAD+ biosynthesis in human 
cells by converting NAD+/NMN to NR which, in turn, 
can cross the plasma membrane and be phosphorylated 
intracellularly to NMN [25]. In in vitro cell systems, 
we demonstrated that when CD73 is either silenced or 
pharmacologically inhibited, the salvage of FK866-treated 
cells by extracellular NMN is reduced [25]. 
An increased CD73 expression has been observed in 
several types of cancer, and the tumor microenvironment 
contains factors promoting CD73 expression [30]. High 
CD73 expression and activity confer a survival advantage 
to cancer cells, frequently determining metastasis and a 
poor prognosis [31]. Up to now, however, CD73 role in 
cancer has always been ascribed to the CD73-mediated 
extracellular production of adenosine and to the regulation 
of purinergic receptor activity [32–35]. Indeed, CD73 is 
considered an appealing therapeutic target for treating 
cancer and the CD73 inhibitor α, β-methylene adenosine 
5′-diphosphate (APCP) shows promising anticancer 
activity, by inhibiting CD73-mediated functions in tumor 
cells and in T-cell immunity [33, 36, 37].
Epithelial ovarian cancer (EOC) is the most lethal 
gynecologic malignancy worldwide, with a 5-year survival 
of less than 30% for the women diagnosed at advanced 
stage [38]. Thus, advances in the identification of new 
therapeutical strategies are demanded. 
Here, we investigated the anti-tumor potential of 
simultaneously inhibiting NAMPT (with FK866) and 
CD73 (with APCP) in an in vitro and in vivo human 
ovarian carcinoma model. Blocking CD73 would hamper 
the generation of NR to be used as an intracellular NAD+ 
precursor by cancer cells, thereby leading to a marked 
potentiation of FK866 anticancer effects (Figure 1A).
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RESULTS
Identification of the NAD+ biosynthetic pathways 
in OVCAR-3 cells
The ovarian cancer cell line OVCAR-3 is 
an established model for in vivo studies of cancer 
therapeutics: their intraperitoneal inoculation leads to a 
local dissemination with formation of tumor masses and 
ascites, in which it is possible to measure the amount 
of extracellular metabolites. To verify that OVCAR-3 
cells represented an appropriate model for our study, we 
preemptively assessed i) the NAD+ biosynthetic pathways 
that are active in these cells, ii) their sensitivity to FK866, 
and iii) the expression of CD73. 
Since NAD+ can be synthesized from various 
precursors and through different pathways [5], we 
screened which of these pathways are present in 
OVCAR-3 cells. Specifically, the activities of NAMPT 
(converting NAM to NMN), nicotinamide riboside 
kinase (NRK; phosphorylating NR to NMN), and 
of nicotinate phosphoribosyltransferase (NAPRT; 
converting NA to NAMN), were measured in OVCAR-3 
cell extracts. In addition, the activity of quinolinate 
phosphoribosyltransferase (QAPRT), involved in the 
de-novo synthesis of NAD+ from tryptophan, was also 
tested. As shown in Figure 1B, both NAMPT and NRK 
activities could be detected in OVCAR-3 cells, indicating 
that these cells are able to use both NAM and NR as 
NAD+ precursors. In humans, NRK activity is expressed 
by two different isoforms, which can be enzymatically 
distinguished based on kinetic parameters [39]. The 
fact that the NRK activity in OVCAR-3 cell lysates, as 
assessed in the presence of 72 µM NR, was similar to 
the one measured in the presence of 36 or 18 µM NR, 
i.e. below the Km for NR of the NRK2 isoform (46 µM, 
Figure 1: OVCAR-3 cells are sensitive to NAMPT inhibition with FK866. (A) Schematic representation of the rationale 
for simultaneously inhibiting CD73 and NAMPT. (B) Screening of the NAD+ biosynthetic enzyme activities performed on cell lysates 
from untreated OVCAR-3 cells (black bars) or from cells treated for 24 h with 30 nM FK866 (white bars). Results are mean ± SD of 3 
determinations. *p < 0.001. (C) OVCAR-3 cells were incubated for 48 h with 30 nM FK866, in the presence of 10 µM NMN, NR, QA or 
of 100 µM PA. Results are mean ± SD of at least 3 determinations. *p < 0.01 compared to FK866 alone. 
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ref. 39), indicates that the main NRK activity is due to 
the expression of NRK1 (Km for NR, 3.4 µM, ref. 39) 
(Supplementary Figure S1). When OVCAR-3 cells were 
incubated for 24 h in the presence of FK866, NAMPT 
activity was almost completely inhibited, whereas the 
other enzymatic activities were not affected (Figure 1B): 
thus, NAMPT inhibition with FK866 does not alter the 
enzymatic activity of the other enzymes involved in 
NAD+ synthesis. The intracellular NAD+ concentration 
was greatly reduced by a 48 h-incubation with 30 
nM FK866 (from 19.12 ± 4.88 to 0.40 ± 0.12 nmol/
mg proteins), indicating a major role for the NAMPT-
mediated NAD+ production in OVCAR-3 cells. The 
exogenous addition of NMN or NR reverted FK866-
induced NAD+ reduction (Figure 1C). NAPRT activity 
was not detectable in these cell extracts, whereas QAPRT 
was the most abundant activity (Figure 1B). The de-novo 
route controlled by QAPRT is considered not relevant 
in most cell types, under physiological conditions [5]. 
To analyze the contribution of QAPRT activity to NAD+ 
maintenance in OVCAR-3 cells, cells were incubated in 
the presence of quinolinic acid (QA). No increase in their 
intracellular NAD+ concentration was observed in control 
(20.80 ± 3.52 nmol/mg proteins) or in FK866-treated 
cells (Figure 1C). Accordingly, addition of phthalic acid 
(PA), a QAPRT inhibitor, failed to affect the intracellular 
NAD+ levels under either type of treatment conditions 
(control+ phthalic acid: 20.98 ± 2.87 nmol/mg proteins; 
FK866+ phthalic acid: Figure 1C). All together, these 
results indicate that in OVCAR-3 cells QAPRT does not 
significantly contribute in maintaining NAD+ levels. The 
significance of the marked QAPRT activity measured 
in the lysate of these cells remains to be elucidated. 
The possibility that during the preparation of the lysate 
an inhibitory factor of the enzyme has been removed or 
diluted cannot be ruled out, as occurred in [40]. In this 
view, in ovarian carcinoma cells, QAPRT activity might 
become relevant to NAD+ production only under specific, 
still unknown conditions. For instance, it has been reported 
that neoplastic transformation in astrocytes is associated 
with a QAPRT-mediated switch in NAD+ synthesis, 
whereby glioma cells begin to utilize microglia-derived 
QA as an alternative NAD+ precursor thereby acquiring 
resistance to radiochemotherapy [41]. 
CD73 inhibition reduces the NMN-mediated 
rescue of FK866-induced death in OVCAR-3 
cells
Next, we assessed CD73 expression in OVCAR-3 
cells. At first, we evaluated the presence of ectocellular 
AMP-degrading activity, which was 71.9 ± 12.1 nmol 
adenosine/min/mg protein, as measured using intact 
cells. A qPCR analysis also confirmed presence of 
CD73 mRNA in OVCAR-3 cells, which was reduced 
by 85% at 24 h after transfection with CD73-siRNA 
(Figure  2A). In accordance, Western blot analysis 
on cell lysates from OVCAR-3 cells, also revealed 
a band approximately at a 70 kDa molecular weight, 
which was decreased by 65% in cells transfected with 
CD73-siRNA (Figure  2B). CD73-silencing greatly 
reduced the AMP-degrading activity (Figure 2C), 
confirming that this enzymatic activity reflected the 
presence of CD73, and not of other enzymes. Finally, 
CD73 expression on intact cells was also demonstrated 
by FACS analysis (Supplementary Figure S2). Since 
extracellular NAD+/NMN might also be a substrate for 
CD38, being hydrolyzed to NAM [25, 42], we evaluated 
CD38 enzymatic activities in OVCAR-3 cells: however, 
no detectable production of NAM and ADPR from 
NAD+, nor of NAM and cyclic-GDP-ribose from NGD+ 
(a NAD+ analogue used to measure the CD38-mediated 
ADP-ribosyl cyclase activity, ref. 43) could be detected 
(data not shown).
We previously showed that, in U87 (human 
glioblastoma) and A549 (human lung) cells, CD73 
silencing or its pharmacological inhibition with APCP 
prevented the rescue from FK866 cytotoxicity by NMN 
supplementation [25]. In line with this observation, CD73-
silencing reduced by 70% the ability of FK866-treated 
OVCAR-3 cells to generate intracellular NAD+ using 
extracellular NMN (Figure 2D). 
The presence of 30 nM FK866 for 72 h in the culture 
media greatly reduced (by approximately 90%) OVCAR-3 
cell viability, and extracellular NMN completely rescued 
cells from the FK866-induced cell death (Figure 2E, 
control cells), as previously shown for other cell lines [25]. 
When CD73 expression was down-regulated, the NMN-
mediated rescue of the FK866-induced cell death was 
significantly reduced (Figure 2E). Similar measurements 
of cell viability in the presence of the specific CD73 
inhibitor APCP, indicated that APCP per se did not affect 
viability of control or of FK866-treated cells, whereas 
it significantly alleviated the protective effects of 
exogenously added NMN on FK866-treated malignant 
cells (Figure 2F). These data indicate that CD73 activity 
is necessary for utilization of extracellular NMN to fuel 
intracellular NAD+ synthesis and thereby rescue cells from 
the FK866-induced cell death.
To conclusively demonstrate that NMN, in order 
to be utilized by cells, is converted into NR, which can 
cross the plasmamembrane through a dypiridamole-
inhibitable nucleoside transporter [44], OVCAR-3 cells 
were incubated, or not, with FK866, NR, or NMN, with 
or without dypiridamole. Dypiridamole almost completely 
abrogated the NR-mediated rescue of FK866-treated cells 
and greatly inhibited the rescue obtained with NMN, both 
in terms of intracellular NAD+ content (Figure 3A) and 
of cell viability (Figure 3B). The effects of dypiridamole 
are in line with the idea that NR influx into cells has to 
occur to ensure cell rescue from FK866 by NMN (or NR 
itself). Finally, NRK1 expression was specifically silenced 
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in OVCAR-3 cells: qPCR analysis performed 24 h after 
transfection with NRK1-specific siRNA demonstrated a 
65 ± 15% (n = 3) reduction in NRK1 mRNA levels. In 
NRK1-silenced cells, both NR- and NMN-mediated rescue 
from FK866-induced NAD+ depletion (Figure 3C) and cell 
death (Figure 3D) were potently and significantly reduced.
Figure 2: Silencing of CD73 expression or pharmacological CD73 inhibition impairs the NMN-mediated rescue from 
FK866-induced cell death. (A–E) OVCAR-3 cells were transfected in the presence of a specific CD73-siRNA or negative control-
siRNA (control-siRNA). Twenty four hours after transfection: qPCR analysis (A), Western blot analysis (B), and evaluation of the AMP-
degrading activity (C) were performed; (D–E) After 24 h after electroporation, cells transfected with control-siRNA (white bars), or with 
CD73-siRNA (black bars), were treated (or not) with 30 nM FK866, in the presence or absence of NMN (added twice/day at 10 µM final 
concentration) and NAD+ content (D) and cell viability (E) were evaluated after 48 and 72 h, respectively. Cell viability is expressed as % 
of untreated cells. Data are mean ± SD (n = 3). In panel B, one representative blot and the mean ± SD of 3 different analysis are shown 
*p < 0.05. (F). OVCAR-3 cell viability (5 × 103 well in 96-well plates) was evaluated after 72 h incubation of the cells in complete medium 
with or without 30 nM FK866, in the presence or absence of 1 µM adenosine 5′-(α, β-methylene)diphosphate (APCP), or of 10 µM NMN 
(added twice a day). Results are expressed as percentage of cell growth relative to untreated, control cells. Data are expressed as mean ± 
SD (n = 3). *p < 0.05, compared to FK866+ NMN-treated cells. 
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Figure 3: Inhibition of NR transport or silencing of NRK1 expression impairs the NMN-mediated rescue from FK866-
induced NAD+ depletion and cell death. (A–B) OVCAR-3 cells were incubated for 48 h in the presence of 30 nM FK866, with (grey 
bars) or without (white bars) 5 µM dipyridamole (dyp) and NMN or NR (added twice/day at 10 µM final concentration), as indicated. 
NAD+ content (A) and cell viability (B) were evaluated after 48 h. Cell viability was expressed as relative to control, untreated cells. 
(C, D) OVCAR-3 cells were transfected in the presence of a specific NRK1-siRNA (black bars) or negative control-siRNA (white bars). 
Twenty four hours after transfection, cells were treated (or not) with 30 nM FK866, in the presence or absence of NMN or NR (added twice/
day at 10 µM final concentration): NAD+ content (C) and cell viability (D) were evaluated after 48 h and 72 h, respectively. Results are the 
mean ± SD of at least 3 independent determinations. *p < 0.05.
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Combined treatment with NAMPT and CD73 
inhibitors affects tumor NAD+, NMN and ATP 
content
The data obtained in vitro in OVCAR-3 cells 
suggested that this cell line was suitable for investigating 
whether the simultaneous administration of FK866 and 
APCP would result in a more robust reduction in the 
intracellular NAD+ content in an in vivo cancer model. 
Thus, an in vivo experiment was conducted utilizing 
athymic nude mice that were inoculated intraperitoneally 
with OVCAR-3 cells stably transfected with firefly-
luciferase. The expression of firefly-luciferase by the 
cancer cells allowed us to monitor tumor development 
by in vivo bioluminescence using the IVIS™ Imaging 
System. Mice were randomized to the following treatment 
groups: vehicle, FK866, APCP or the combination of 
the two molecules. Animals were treated for 28 days: 
body weight measurements and general physical status 
recordings indicated the absence of major toxicities as a 
result of these treatments throughout the treatment period.
NAD+, NMN and ATP levels were evaluated both in 
the recovered tumor mass and in ascitic exudates. NAD+ 
content in the tumors was more pronouncedly decreased 
in animals treated with the combination of the two 
molecules than with FK866 alone (Figure 4A), confirming 
that NAMPT and CD73 inhibition affect two different 
pathways of intracellular NAD+ biosynthesis. Consistent 
with these data, NMN levels within tumor masses were 
found to be significantly reduced in the combination 
treatment arm, as compared to those measured in mice that 
had been treated with FK866 alone (Figure 4B), which is in 
keeping with the involvement of NMN as an intermediate 
metabolite of both NAMPT- and NRK-mediated pathways 
of NAD+ production (Figure 1A). Finally, intratumor ATP 
levels were also strongly decreased by the simultaneous 
inhibition of NAMPT and CD73 (Figure 4C), which is 
consistent with previous studies reporting that inhibition 
of NAD+ biosynthesis also affects ATP content [14, 45]. 
APCP alone did not significantly decrease intratumor 
NAD+, NMN and ATP levels, as compared to control 
animals (Figure 4), suggesting that, under baseline 
conditions, within a tumor, NAD+ is primarily synthesized 
from NAM. 
Next, since the presence of extracellular NAD+ and/
or NMN in the fluids surrounding the tumor represents 
a fundamental pre-requisite to verify the hypothesis that 
interfering with the utilization of extracellular NAD+/
NMN by inhibiting CD73 activity could enhance the 
anti-tumor activity of FK866, we measured NAD+ and 
NMN levels in the ascitic exudates collected from the 
animals at sacrifice. Indeed, both NAD+ and NMN could 
be detected in the untreated controls (Figure 4D, 4E). In 
animals treated with the combination therapy, both NAD+ 
and NMN levels were strongly reduced, indicating that 
the levels of extracellular nucleotides indeed mirror the 
intracellular values (Figure 4D, 4E). In FK866-treated 
animals, NAD+ and, more remarkably, NMN levels 
were decreased compared to those measured in exudates 
from control animals (Figure 4D, 4E). ATP levels were 
significantly lower in exudates from animals treated 
with the combination therapy, as it was observed for 
the intracellular ATP content. The observation of higher 
ATP levels in APCP-treated animals (Figure 4F) could be 
explained by the absence of downstream AMP degradation 
to adenosine due to CD73 inhibition by APCP.
Interestingly, NR was indeed detectable in ascitic 
exudates, which is in agreement with the presence of the 
ectocellular CD73 activity in tumor cells. Low NR values, 
ranging from 3 nM to 68 nM, were measured in the 
tested samples, which might suggest a marked uptake of 
extracellular NR [44]. A high degree of variability in NR 
levels was observed within ascitic exudates within group 
of treatment, which might reflect NR values that were very 
close to the detection limit of our method. As a result, no 
comparison between the different treatments under this 
respect (effects on extracellular NR levels) was possible. 
Simultaneous administration of NAMPT and 
CD73 inhibitors differently affects NAD+ content 
in hearts and livers
The effects of the different treatments were also 
evaluated by measuring NAD+ levels in hearts and livers. 
As shown in Figure 5A, the pattern of NAD+ levels in the 
heart after the different treatments essentially paralleled 
the NAD+ levels that were detected in the tumors. FK866 
treatment significantly reduced intracellular NAD+ levels 
in hearts (Figure 5A), in line with a previous report [46]. 
Interestingly, CD73 activity appeared to be relevant 
for the maintenance of intracellular NAD+ content 
in the heart, too, since the simultaneous inhibition of 
NAMPT and CD73 decreased heart NAD+ levels to a 
higher extent as compared to NAMPT inhibition alone 
(Figure 5A). 
In contrast with what observed in tumors and hearts, 
treatment with FK866 increased NAD+ levels in the liver 
(Figure 5B). This observation is in agreement with results 
obtained with a different NAMPT inhibitor (administered 
to mice for 5 days), which also did not reduce liver NAD+ 
content [47]. However, simultaneous inhibition of CD73 
and NAMPT did significantly reduce (by approximately 
25%) liver NAD+ content as compared to the NAD+ 
content measured in FK866-treated animals.
In vivo antitumor effect of NAMPT and CD73 
inhibition
We next aimed to evaluate the effect of combined 
NAMPT and CD73 inhibition on tumor cell proliferation and 
necrosis. To this end, we carried out immunohistochemical 
analyses on paraffin-embedded tissue sections of tumors 
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Figure 4: NAD+, NMN and ATP levels in tumors and in ascitic exudates from control and treated mice. NAD+ (A, D), 
NMN (B, E) and ATP (C, F) levels were measured in tumors (A, B, C) or in ascitic exudates (D, E, F) recovered from the animals treated 
with vehicle (control), or FK866 or APCP or their combination. Results represent the mean ± SD (tumors, n = 8; ascitic exudates, at least 
n = 5). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. 
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from animals treated (or not) with FK866, APCP, or 
FK866 plus APCP for 28 days. As shown in Figure 6A, 
FK866 plus APCP-treated tumors contained a statistically 
significant lower proportion of Ki67 positive proliferating 
cells compared to control tumors. A representative staining 
with anti-Ki67 mAb of tumors from the different treatment 
arms is shown in Figure 6A. Histological analysis of 
paraffin-embedded sections from control tumor and treated 
tumors demonstrated that the percentage of necrosis was 
significantly increased in both FK866- and APCP-treated 
tumors, but the most potent effect was documented in the 
combination treatment arm (Figure 6B). 
Finally, the combination FK866 plus APCP was the 
only treatment that significantly, albeit slightly, improved 
mice survival compared to vehicle (Figure 6C).
DISCUSSION
Lowering intratumor NAD+ concentration is 
currently considered a promising strategy to treat cancer 
and major efforts are directed to the identification of 
clinically applicable NAMPT inhibitors [6–8, 13, 48]. 
In this study, we investigated whether the beneficial 
antitumor effects of NAMPT inhibition could be 
circumvented in vivo by the presence of NAD+ or NAD+ 
precursors, such as NMN or NR in the extracellular 
milieu, since these metabolites can potentially fuel NAD+ 
production through alternative pathways [25]. Several 
lines of evidence obtained in vitro, demonstrated that in 
OVCAR-3 cells, similarly to what previously reported for 
U87 and A549 cells [25], CD73 expression also generates 
NR from extracellular NMN, circumventing the anticancer 
effects of NAMPT inhibition. Specifically, the NMN-
mediated rescue from FK866-induced NAD+ depletion 
and cell death were impaired by: i) CD73 silencing or 
inhibition with APCP (Figure 2D, 2E, 2F); ii) inhibition 
of NR transport (Figure 3A, 3B); iii) NRK1 silencing 
(Figure 3C, 3D). The fact that, in FK866-treated cells, 
NMN completely rescued cells from death (Figures 2E, 
2F and 3B, 3D), while increasing NAD+ content above 
10% of the control value (Figures 1C, 2D, 3A, 3C), and 
not to a complete restoration to values in untreated cells 
(i.e. approximately 20 nmol/mg proteins), is in line with 
the observation that cell death occurs when NAD+ levels 
are depleted to less than 5% [45].
Figure 5: NAD+ levels in hearts and livers from control and treated mice. NAD+ levels were measured in hearts (A) and livers 
(B) recovered from the animals treated with vehicle (control), or FK866 or APCP or their combination. Results are expressed as nmol/g 
tissue and represent the mean ± SD (n = 8). *p < 0.05; **p < 0.01; ****p < 0.0001. 
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The most relevant result obtained in this study is 
represented by the proof of concept that the combined 
inhibition of NAMPT and CD73 indeed results in a 
significant reduction in NAD+ and NMN concentration in 
tumors in vivo (Figure 4), leading to a reduced tumor cell 
proliferation, increased necrotic tumor cell death and to 
a significant, albeit small, advantage in terms of survival 
(Figure 6).
The results on NAD+ levels in tumors, heart and 
liver indicate that also in vivo, the intracellular NAD+ 
content is quantitatively related to the ectoenzymatic 
activity of CD73, as previously demonstrated in vitro in 
different cell lines [25]. The contribution of the different 
NAD+ biosynthetic pathways and the relevance of the 
utilization of extracellular NAD+ precursors to NAD+ 
synthesis may differ among different organs and tissues. 
In the heart, NAMPT inhibition determined a significant 
decrease in the intracellular NAD+ content (Figure 5), 
in agreement with our previous findings [46] and with 
our previous observation that NAMPT activity is a key 
contributor to NAD+ synthesis in this organ [49]. The 
concomitant inhibition of CD73 by APCP determined 
a further decrease of the intracellular NAD+ content, 
indicating that also in heart CD73 enzymatic activity 
Figure 6: Antitumor effects of administration of FK866, APCP and FK866+ APCP in OVCAR- 3 bearing mice. 
(A, B) Tumors were collected from animals treated for 28 days with vehicle (control), or FK866 or APCP or their combination: tumor tissue 
sections were stained with an anti-Ki67 antibody (A) or with Hematoxilyn/Eosin solution (B); the number of Ki67+ cells was evaluated in 
randomly chosen fields from different samples (n = 5 fields/sample); the necrotic areas were quantified using the Image J program and results 
represent the percentage of necrotic area relative to the total section and are the mean ± SD of at least 4 samples. *p < 0.05; **p < 0.01; ***p < 
0.001. Representative images are shown. (C) Animals were treated with vehicle (control, black), or FK866 (blue) or APCP (red) or their 
combination (green) and were sacrificed when they showed signs of poor health. Survival curves were constructed by using the Kaplan–
Meier method. Statistical analysis of different treatment groups was performed by Peto’s log-rank test. *p < 0.05 vs black, blue and red lines.
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contributes to the generation of intracellular NAD+. 
Indeed, the presence of a NRK activity has been 
demonstrated in this organ [49]. Conversely, in the liver, 
FK866 failed to cause a reduction in NAD+ content, in 
agreement with previous reports, in which the relevance 
of circulating levels of metabolites, other than NAM, 
fueling NAD+ synthesis in this organ is suggested, and in 
which the presence of a robust activity of the enzymes 
responsible for their conversion to NAD+ is proven [46, 
49]. The fact that the simultaneous inhibition of CD73 and 
NAMPT significantly reduces (by approximately 25%) 
hepatic NAD+ content, compared to the content in FK866-
treated animals (Figure 5B), indicates a contribution by 
CD73-mediated extracellular NR generation to NAD+ 
biosynthesis in this organ. Consistent with this notion, 
the presence of a NRK activity has been previously 
demonstrated in the liver [49] and NR supplementation 
to mice was found to increase NAD+ content in liver, 
muscle and brown adipose tissue [50]. Thus, NAMPT 
contribution to intracellular NAD+ levels appears to 
vary between different organs, tissues and tumors. In the 
case of the tumor cells used for this study, NAMPT and 
NRK seem to play a major role in NAD+ biosynthesis, 
as the simultaneous inhibition of NAMPT and CD73 
significantly decreased intracellular NMN and NAD+ 
concentration (Figure 4). It is noteworthy to highlight that 
this result is in agreement with the data obtained by the 
screening that was preemptively performed to identify 
which NAD+-biosynthetic enzymatic activities are present 
in this cell line (Figure 1B). Indeed, this result strengthens 
the idea that identifying the contribution of each enzyme 
to NAD+ biosynthesis in various tissue/cell types, is crucial 
for the rational design of successful therapeutic strategies 
aimed at modulating NAD+ metabolism [49]. Currently, 
no specific inhibitors for NRK are available yet: their 
identification might prove useful in combined therapies to 
reduce NAD+ levels in tumors, depending on the relative 
contribution of this enzyme.
Our data show for the first time that NAD+, NMN 
and NR are present in ascitic exudates. NAD+ has been 
previously detected in mammalian plasma and fluids 
[26]. Regarding NMN, few data are available to prove its 
presence in murine plasma [27, 51]. This study represents 
the first report of NR detection in murine fluids. 
The detection of the extracellular NAD+, NMN 
and NR was obviously very important for our working 
hypothesis. Interestingly, by inhibiting CD73 activity, an 
increase in extracellular NAD+ and/or NMN was expected 
(see Figure 1A): instead, this was not documented 
by our measurements in ascitic exudates (Figure 4). 
Nevertheless, the interpretation of these results is difficult 
since the levels of these nucleotides may also reflect the 
activity of ectoenzymes other than CD73, as well as the 
intracellular content of the same nucleotides. Indeed, 
NAD+ and NMN concentrations in the ascitic exudates 
seems to correlate with their intratumoral concentration 
(Figure 4). The marked decrease in the levels of 
extracellular NAD+ and ATP that was obtained with 
the combination of FK866 and APCP (Figure 4) might 
prove beneficial from a therapeutic prospective and also 
provides mechanistic insights on the well-known role 
of the tumor microenvironment in the control of tumor 
growth and tumor-related inflammation. In this context, 
extracellular NAD+ and ATP have been demonstrated to 
represent pro-inflammatory stimuli [52, 53]. Specifically, 
extracellular NAD+ levels in the low micromolar range, 
such as those detected in our ascitic exudates, effectively 
stimulate innate immune responses [52].
In a previous study of human ovarian cancer 
xenografts generated by subcutaneous injection of A2780 
cells in mice, the expression of the proliferation marker, 
Ki67, within the tumors was significantly reduced by 
FK866 [54]. In our model (OVCAR-3 xenografts) the use 
of FK866 alone did not reduce the number of Ki-67+ cells, 
or significantly affect animal survival (possibly due to 
the lower dose of FK866 used in our study, i.e. 10 mg/Kg 
instead of 15 mg/Kg [54]). However, a reduction in tumor 
cell proliferation (as revealed by immunohistochemistry 
on tumor sections), accompanied by a consistent 
increase in survival, was observed in response to the co-
administration of FK866 together with APCP (Figure 6A, 
6C). These effects nicely correlated with the observed 
reductions in NAD+ and ATP levels. The lower number 
of proliferating cells in tumors from mice treated with 
FK866 plus APCP was also accompanied by the presence 
of larger necrotic areas (Figure 6B). 
CD73 is emerging as an appealing target in cancer 
therapy, especially for its key role as an immuno-
suppressive factor within the tumor microenvi ronment. 
Small molecular inhibitors and monoclonal antibodies 
against CD73 have been recently developed [55, 56], and 
our data indicate that combinations of NAMPT inhibitors 
and CD73-targeting agents might prove clinically 
effective.
Regarding the translational relevance of our results, 
recently it has been demonstrated that, in line with what 
reported for other tumor tissues [30–37, 57], CD73 is 
associated with poor prognosis in high-grade serous 
ovarian cancer, representing a prognostic marker of patient 
survival [58]. From a study on patients affected by EOC 
(subdivided on the basis of different clinicopathologic 
variables), it was inferred that tumors exhibit various levels 
of CD73 expression. In that study, 29.9% of the patients 
had CD73– tumors, and the rest had a variable level of 
CD73 expression, with CD73 being more frequently 
expressed in mucinous and in clear cell carcinoma, 
compared to serous and endometriod adenocarcinoma 
[59]. Thus, a personalized treatment approach that takes 
into account CD73 expression could be considered. 
Unexpectedly, in the latter study, the CD73+ ovarian 
cancer group (mostly including patients with mucinous 
adenocarcinoma) showed better prognosis and the authors 
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speculated that cell differentiation stage had more influence 
on the prognosis than the adverse effect of CD73 [59]. 
In another clinical study, it was demonstrated that 
CD73 is highly expressed by mesenchymal-like and also, 
to a lower level, by epithelial-like cells isolated from 
ascites or cancer tissue from patients with EOC [60]. 
In fact, an advantage of the combination of NAMPT 
inhibitors with CD73 inhibitors is that their synergism 
could be achieved regardless of whether NR production 
from extracellular NAD+/NMN is catalyzed by CD73 
harbored on epithelial or on mesenchymal-like cells. 
Finally, it was reported that CD117+/CD73+ fibroblast-like 
stromal cells are significantly associated with poor clinical 
manifestations and poor survival probability in ovarian 
carcinomas, and further studies of CD73+ stromal cell-
targeting therapies in EOCs were thought to be important 
[38]. Thus, targeting CD73 could prove beneficial under 
several respects, directly targeting NAD+ biosynthesis in 
the malignant epithelial cells (as those used in our study), 
but also preventing CD73 activity on the stromal cells that 
are present within the tumor, which might contribute to 
the generation of NR and adenosine in the tumor 
extracellular microenvironment and thereby promote 
tumor growth [61]. 
In conclusion, our study demonstrates that the 
CD73 inhibitor APCP can enhance the antitumor activity 
of FK866 in ovarian cancer cells. The potentiation of 
FK866 with APCP occurs through an enhancement of the 
depletion of NAD+ and ATP that is initiated by FK866, 
ultimately resulting in tumor growth inhibition and 
necrotic tumor cell death. This study provides the proof-
of-concept that combining NAMPT and CD73 inhibitors 
might prove clinically beneficial and warrants further 
investigations of this approach in other models and then, 
potentially, in clinical trials.
MATERIALS AND METHODS
Drugs
All chemicals were purchased from Sigma (Milan, 
Italy), unless otherwise stated. FK866 was in part 
generously provided by the NIMH Chemical Synthesis 
and Drug Supply Program and in part purchased from 
Sigma. NR was enzymatically synthesized from NAD+ as 
described [25]. 
Cell culture
OVCAR-3 cells (human ovarian cancer cells), 
transfected with fire fly-luciferase, obtained as described 
in [62] were grown in RPMI1640 supplemented with 10% 
fetal calf serum, penicillin (100 U/ml) and streptomycin 
(100 µg/ml) at 37°C in a humidified atmosphere with 
5% CO2.
CD73 and NRK1 siRNA gene silencing
OVCAR-3 cells were transfected with Stealth™ 
RNAi (Life Technologies Italia, Monza, Italy) targeting 
human CD73 (Oligo ID: HSS101578) or with Mission 
esiRNA (Sigma) targeting human NRK1 (Oligo ID: HU-
09786–1). Cells were electroporated with 2 µM duplex 
siRNA with the Nucleofector System, using the Cell 
Line Nucleofector Kit V, program V-005, following the 
manufacturer’s instructions. As control, OVCAR-3 cells 
were transfected with StealthTM RNAi Negative Control 
Duplex (Life Technologies Italia) for CD73 or with Mission 
negative control (Sigma) for NRK1. Cells were seeded as 
follows: 2×105 onto 35×10 mm tissue culture dishes for 
mRNA quantification; 2×105 cells/well in 12-well plates for 
the determination of intracellular NAD+ levels; 5×103 cells/
well in 96-well plates for viability assays. All experiments 
were carried out 24 h after transfection.
qPCR analyses
Twenty-four h after transfection, total RNA was 
extracted from OVCAR-3 cells using the RNeasy Micro 
Plus Kit (Qiagen, Milan, Italy). Quality and quantity of 
RNA were analyzed using a NanoDrop spectrophotometer 
(Nanodrop Technologies, Wilmington, DE). cDNA (0.5 
µg) was synthesized by using iScript cDNA Synthesis Kit 
(Bio-Rad Laboratories, Milan, Italy). PCR primers were 
designed by using through Beacon Designer 2.0 Software 
(Bio-Rad) and their sequences were as follows: hCD73: 
5′-GCTCGGCTCTTCACCAAG -3′ (forward), 5′-TCAGT 
CCTTCCACACCATTAT -3′ (reverse); hNRK1: 5′-AAG 
CCCCTTGACACTATATGGA-3′ (forward), 5′-TCTGG 
AGGCTGATAGACCCT-3′ (reverse); hGAPDH: 5′-CCTG 
TTCGACAGTCAGCCG-3′ (forward), 5′-CGACCAAA 
TCCGTTGACTCC -3′ (reverse); hHPRT1: 5′-GGTCA 
GGCAGTATAATCCAAAG-3′ (forward), 5′-TTCATTAT 
AGTCAAGGGCATATCC-3′ (reverse). 
Statistical analyses of the qPCR were obtained using 
iQ5 Optical System Softwar version 2.0 (Bio-Rad) based 
on the 2–∆∆Ct method, which calculated relative changes in 
gene expression of the target normalized to GAPDH and 
HPRT-1. Experiments were repeated 3 times in triplicate.
Western blot analyses
Twenty-four h after transfection, level of CD73 
expression were evaluated on cell lysates from control 
and silenced cells by Western Blot analysis, performed 
as described in [25] and visualized with the following 
antibodies: anti-CD73 (SAB1306278–40TST, Sigma), 
anti-vinculin (kindly provided by Prof. E. Turco, 
University of Torino, Italy). Western blots were developed 
with the ECL-PLUS kit (GE Healthcare), according 
to the manufacturer’s instructions. Band detection and 
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densitometry were performed using the Chemi-Doc 
System and the quantity one software package (Bio-Rad). 
Determination of intracellular NAD+ levels
OVCAR-3 cells (not transfected, transfected with 
negative control siRNA or with siRNA targeting CD73 or 
NRK1) were plated at a density of 105 cells/well in 12-well 
plates and cultured in 500 µl of complete RPMI1640 in 
the presence or absence of 30 nM FK866 and, depending 
on the experimental setting, with or without 5 µM 
dypiridamole, and supplemented twice a day (at 9 am and 
at 6 pm) for 2 days, with or without 10 µM of NMN or 
NR. Then, cells were harvested and lysed in 0.05 ml of 0.6 
M PCA at 4°C. Cell extracts were centrifuged for 3 min 
at 16, 000 x g, the supernatants were collected and an 
aliquot was diluted 20-fold in 100 mM sodium phosphate 
buffer, pH 8.0, for determination of NAD+ content, as 
described [63]. NAD+ values were normalized to protein 
concentrations, determined by Bradford assay [64].
Cell viability assays
OVCAR-3 cells (5×103/well in 96-well plates; not 
transfected, transfected with negative control siRNA or 
with siRNA targeting CD73 or NRK1) were incubated in 
the presence or absence of 30 nM FK866, with or without 
1 µM adenosine 5′-(α, β-methylene)diphosphate (APCP), 
with or without 5 µM dypiridamole, and, supplemented (or 
not) twice a day (at 9 am and at 6 pm) for 2–3 days, with or 
without 10 µM NMN or NR. Cell viability was measured 
as described [25]. 
Assays of ectocellular AMP-degrading enzyme 
activity
The ectocellular enzymatic activity of CD73 was 
assayed by incubating not transfected, transfected with 
negative control siRNA or with CD73-targeting siRNA, 
OVCAR-3 intact cells (0.5×106 in 0.5 ml of phosphate 
buffered saline, PBS) in the presence of the substrate 
AMP (0.2 mM). At various times (0, 1, 2.5 and 5 min), 
100-μl aliquots of the incubations were withdrawn, briefly 
centrifuged, and 2.5% trichloroacetic acid (TCA) was 
added to 90-μl supernatants. Samples were centrifuged and 
the excess TCA removed with diethylether. The amounts 
of adenosine produced were determined by the phosphate 
HPLC analysis described previously [25]. 
Assay of ectocellular CD38 activity on NAD+ or 
NGD+
Ectocellular enzymatic activities of CD38 were 
assayed by incubating 0.5×106 OVCAR-3 intact cells in 
0.5 ml of PBS in the presence of the substrates NAD+ or 
NGD+ (0.5 mM). At various times (0, 10 and 60 min), 
100-μl aliquots of the incubations were withdrawn, briefly 
centrifuged, and 2.5% trichloroacetic acid (TCA) was 
added to 90-μl supernatants. Samples were centrifuged 
and the excess TCA removed with diethylether. The 
production of ADPR (from NAD+) or cGDPR (from 
NGD+) were determined by the phosphate HPLC analysis 
described previously [63]. 
Assays of NAMPT, NRK, NAPRT and QAPRT 
activities
OVCAR-3 cells were incubated (or not) with 30 
nM FK866 for 24 h. Approximately 5×106 OVCAR-3 cell 
pellets were homogenized with 0.2 ml buffer consisting 
of 50 mM TRIS/HCl, pH 7.5, 0.15 M NaCl, 1 mM 
dithiothreitol, 1 mM phenylmethanesulfonyl fluoride, and 
0.002 mg/ml each of leupeptin, antipain, chymostatin and 
pepstatin. Homogenates were centrifuged at 20, 000 x g 
for 10 min at 4°C, and the supernatants were immediately 
used for the assays of enzymatic activities. The 
simultaneous measurement of the four enzymatic activities 
was performed by using the coupled fluorometric assay 
described in [49]. The enzymes’ activity was referred to 
the protein concentration determined according to [63]. 
Flow cytometric analysis
OVCAR-3 cells (0.4 × 106) were harvested, washed 
once with PBS buffer and incubated for 20 min at 37°C 
in the presence (or absence) of the anti-CD73 antibody 
(Sc130006, Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA, USA), in PBS containing 0.5% FBS. Cells were 
washed once with PBS, and incubated for 20 min at 37°C 
in the presence of an anti-mouse secondary antibody 
conjugated with Alexa-576, in PBS containing 0.5% FBS. 
Cells were washed twice with PBS and analyzed using 
a FACS Calibur flow cytometer (Becton Dickinson) by 
acquiring 10,000 events. 
In vivo treatment
Athymic nude mice were intraperitoneally (ip) 
inoculated with 1.5×105 OVCAR-3 cells transfected 
with firefly luciferase. The in vivo bioluminescence 
using IVIS™ Imaging System, performed 5 days after 
inoculation, allowed us to monitor tumor development 
and randomize the mice in the different groups of 
treatment. Thus, animals were divided in four groups, 
treated as follows: vehicle (0.05% dimethyl sulfoxide, 
DMSO), FK866 (10 mg/Kg administered ip once a day for 
28 days), APCP (15 mg/Kg administered ip every other 
day for 28 days) or the combination of the two molecules. 
On the day of sacrifice, tumor samples, heart and liver 
were collected and fixed in 20% buffered formalin, 
routinely processed and embedded in paraffin. One part 
of some of the lesions was embedded in OCT, frozen 
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in liquid nitrogen and stored at –80°C. Ascites exudates 
were collected, centrifuged to discard possible cells and 
immediately frozen in liquid nitrogen. In a second trial, 
conducted as above, animals were sacrificed when they 
showed signs of poor health to evaluate survival.
Determination of NAD+, NMN, ATP and NR 
levels in samples from treated animals
Nucleotides were extracted from tumor, liver 
and heart as described in [46]. Perchloric acid (PCA, 
0.6 M, final concentration, for NAD+, NMN and NR 
determination) or trichloroacetic acid (TCA, 5% v/v, final 
concentration, for ATP determination) was added to the 
ascitic exudates for deproteinization: samples were then 
neutralized by adding K2CO3 (for PCA) or by extraction 
with diethyl ether (for TCA). NAD+ and ATP levels in 
tumors were determined as described [46], and normalized 
to tissue weight (for tumor, liver and heart). ATP levels 
in ascitic exudates were measured on neutralized extracts 
with an ATP determination kit (Invitrogen, Carlsbad, 
CA) following the manufacturer’s instruction. Twenty-µl 
of the extract were added to 180 µl of reaction buffer in 
each well of a 96-well plate. Luminescence was measured 
using a FLUOstar OPTIMA (BMG Labtech, Ortenberg, 
Germany) and ATP concentrations in the samples were 
calculated from the ATP standard curve.
NMN and NR were measured upon derivatization 
with acetophenone and spectrofluorometric HPLC 
analysis. Derivatization was performed by mixing 50 μl 
of the nucleotide extracts with 100 μl KOH 1N and 50 μl 
acetophenone. After 15 min incubation at 4°C, 100 μl of 
formic acid was added and the samples were heated for 
5 min at 100°C. The spectrofluorometric HPLC analysis 
was carried out as described in [65]. Measurements were 
performed by using a duplicate sample analyzed in parallel 
and containing known amounts of NMN and NR spikes.
Immunohistochemical staining of tissues
Immunohistochemical staining of tissue sections was 
performed using the Envision System HRP mouse (Dako). 
Briefly, 5 mm thick sections were cut from formalin fixed, 
paraffin embedded blocks, deparaffinized with xylene and 
rehydrated by passages through decreasing concentrations 
of ethanol (from 100% to 70%). Endogenous peroxidase 
activity was blocked by 30 min incubation at room 
temperature with methanol containing 3% H2O2. Tissue 
sections were then incubated at 98°C for 40 min in EDTA 
1 mM (pH 8.0) for antigen retrieval (Sigma). After rinsing 
in PBS (Sigma), tissue sections were incubated 1 hour at 
Room Temperature with anti-Ki67 (Dako). Tissue sections 
were washed twice in PBS and incubated for 30 min at 
room temperature with Dako Envision System horse 
radish peroxidase (HRP) Mouse. After washing in PBS, 
peroxidase activity was detected by incubating tissue 
sections for 6–10 min at room temperature with Dako 
Liquid DAB Substrate Chromogen System (Dako). Tissue 
sections were counterstained with Mayer’s hematoxylin 
(Sigma). The number of positively stained tumor cells 
in each lesion was evaluated independently by two 
investigators. The variation between the results obtained 
by the two investigators was less than 10%. 
Some sections were processed and stained with 
Hematoxylin/Eosin solution and the necrotic areas were 
quantified using the Image J program.
Statistical analyses
All parameters were tested by paired t test or by 
Two-tailed unpaired t test with 95% Confidence Interval; 
p values < 0.05 were considered significant. In the Figures, 
only relevant comparisons are shown. The statistical 
significance of differential survival between experimental 
groups of animals was determined by Kaplan-Meier 
curves and Peto’s log-rank test by the use of StatDirect 
statistical software (CamCode, Ashwell, UK). All 
statistical tests were two-sided, and P values less than .05 
were considered statistically significant.
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